Institutional review board

BTAI LAWSUIT ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Friday, August 18, 2023
CASE, LLP, Institutional review board, Telephone, COST, Record, Levi, Dementia, Patient, CLASS, NEXT, Court, FDA, Therapy, Agitation, Safety, Medical device, Cryptocurrency

NEW YORK, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were adversely affected by alleged securities fraud between December 15, 2021 and June 28, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    BTAI investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

DEADLINE ALERT for BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Thursday, August 17, 2023
Acceleration, People's Law Office, Mallinckrodt, Institutional review board, BIS, Privacy Office of the U.S. Department of Homeland Security, Face, Chapter 11, Title 11, United States Code, Class, Software, Telephone, Trust, Record, Law, Seagate, Suite, Dementia, Investment, Patient, Nature, Risk, FDA, Science and technology in Asia, Agitation, Safety, Commerce, U.S. Department of Commerce Office of Security, Security (finance), Huawei

BENSALEM, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ImmunityBio, BioXcel, and Seagate and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, August 17, 2023
GMP, Institutional review board, Good manufacturing practice, CMOS, Seagate, Patient, BLA, News, Commerce, Software, U.S. Department of Commerce Office of Security, P.C, Policy, Infection, EAR, Name, Food and Drug Administration, Dementia, FDA, Entity List, Safety, Vaccine, Biologics license application, BIS, Shareholder, Office of Inspector General, U.S. Department of Health and Human Services, Record, Immunotherapy, HDD, Immune system, Defendant, United, Therapy, Agitation, Jordan Economic and Commerce Bureau, Acceleration, Seagate Technology, Person, Nursing, Nature, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Cryptocurrency, Audit, Huawei, ImmunityBio COVID-19 vaccine

The Company offers immunotherapy and cell therapy platforms, including, inter alia, antibody cytokine fusion protein N-803, commercially referred to as “Anktiva”.

Key Points: 
  • The Company offers immunotherapy and cell therapy platforms, including, inter alia, antibody cytokine fusion protein N-803, commercially referred to as “Anktiva”.
  • The Company uses third-party contract manufacturing organizations (“CMOs”) to produce certain of its product candidates, including Anktiva.
  • In May 2022, ImmunityBio submitted a Biologics License Application (“BLA”) for Anktiva to the U.S. Food and Drug Administration (“FDA”).
  • For more information on the Seagate class action go to: https://bespc.com/cases/STX

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI

Retrieved on: 
Wednesday, August 16, 2023
Titan, Institutional review board, Dexmedetomidine, Class, Record, Agitation, Dementia, Patient, Advertising, Court, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, I-Space (Chinese company), Food, Safety, Insurance, Tobacco

WHAT TO DO NEXT: To join the BioXcel Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=17579 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioXcel Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=17579 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

BTAI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc. Shareholders

Retrieved on: 
Wednesday, August 16, 2023
Institutional review board, Telephone, COST, Record, HOW, Dementia, Patient, CLASS, FDA, Therapy, Agitation, Safety, Pharmaceutical industry

NEW YORK, Aug. 16, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws.

Key Points: 
  • NEW YORK, Aug. 16, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws.
  • WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in BioXcel you have until September 5, 2023 to petition the court for lead plaintiff status.
  • Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
  • HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the BTAI lawsuit, please contact J. Klein, Esq.

DEADLINE ALERT for IBRX, BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Tuesday, August 15, 2023
Acceleration, GMP, Institutional review board, BIS, Good manufacturing practice, Privacy Office of the U.S. Department of Homeland Security, Chapter 11, Title 11, United States Code, Software, CMOS, Trust, Record, Law, Complaint, Seagate, Suite, Dementia, Investment, Patient, Nature, Risk, Defendant, FDA, ImmunityBio COVID-19 vaccine, Science and technology in Asia, Agitation, Safety, Commerce, U.S. Department of Commerce Office of Security, Security (finance), Risk management, Mallinckrodt, Huawei

LOS ANGELES, Aug. 15, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Aug. 15, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles

BioXcel Therapeutics, Inc Investors: Please contact the Portnoy Law Firm to recover your losses; September 5, 2023 deadline

Retrieved on: 
Monday, August 14, 2023
Institutional review board, Maintenance, Record, Dementia, Patient, Defendant, FDA, Therapy, Agitation, Pharmaceutical industry

​LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI). investors that a lawsuit filed on behalf of investors that purchased BioXcel securities between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”).

Key Points: 
  • ​LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

RAIN, PTRA, BTAI, Class Action Update: Johnson Fistel Alerts Shareholders of Ongoing Legal Proceedings

Retrieved on: 
Monday, August 14, 2023
Learning, LLP, Institutional review board, Proterra, Action Replay, Record, MANTRA, Dementia, Patient, SAN, Defendant, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Agitation, Food, Safety, Sales, Pharmaceutical industry

SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a law firm specializing in shareholder rights, has announced the initiation of class action lawsuits on behalf of investors of the following companies.

Key Points: 
  • SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a law firm specializing in shareholder rights, has announced the initiation of class action lawsuits on behalf of investors of the following companies.
  • If you suffered a loss and are interested in learning more about being a lead plaintiff, please contact Jim Baker ([email protected]) by email or phone at 619-814-4471.
  • A lead plaintiff will act on behalf of all other class members in directing the class-action lawsuit.
  • An investor's ability to share any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff.

Else Nutrition Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Giant, The Giant Company, Institutional review board, Centers for Medicare & Medicaid Services, Bank statement, Eastern Time Zone, Oklahoma Women's Hall of Fame, WIC, CVS, Stock, Loblaws, Supermarket, Shoppers Drug Mart, Trial of the century, Interest, Medicare, Toddler, Walmart, MD, IRB, Risk, SEDAR, Yoy, Growth, Entrepreneurship, Infant, FDA, BABY, Safety, Grocery store, Online shopping, Bank, Dietary supplement, Amazon

VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC ( BABY ) ( BABYF ) ( 0YL.F ) ("Else" or the "Company") the Plant-Based baby, toddler, and children nutrition company , today reported second quarter 2023 financial results for the period ending June 30, 2023.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC ( BABY ) ( BABYF ) ( 0YL.F ) ("Else" or the "Company") the Plant-Based baby, toddler, and children nutrition company , today reported second quarter 2023 financial results for the period ending June 30, 2023.
  • Management expects to reach over 15,000 listed stores and over 40,000 points of distribution by the end of 2023.
  • Hamutal Yitzhak, CEO of Else Nutrition, commented, “2Q23 was another step forward in our mission to become a global leader in the plant-based nutrition arena.
  • Hamutal Yitzhak, CEO and Co-Founder, will hold a conference call to discuss the quarter's financial results at 10:00 a.m. (Eastern Time) on August 14, 2023.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)

Retrieved on: 
Monday, August 14, 2023
Institutional review board, Record, Suite, Nursing, Food and Drug Administration Amendments Act of 2007, Dementia, Investment, Patient, Court, Defendant, FDA, Therapy, GPM, News, Agitation, Food, Safety, Cryptocurrency, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • BioXcel further disclosed that the fabricated email correspondence was provided to the FDA during an on-site inspection in December 2022.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles